By Elias Schisgall

Strata Critical Medical expects demand for organ transplants, along with acquisitions in what it describes as a fragmented market, to boost revenue next year and fuel double-digit growth through 2029.

The company said at an investor day presentation on Monday in New York that it now projects revenue of $255 million to $270 million in 2026, and sees low double-digit revenue growth through 2029.

The medical services provider, which specializes in logistics for organ transplants, last week raised its revenue guidance for the current year to between $185 million and $195 million, from $180 million to $190 million previously.

Strata said high transplant demands would lead to high levels of organic growth before any capital expenses. It also plans to take advantage of a fragmented market for organ recovery and transit services through acquisitions, allowing Strata to capitalize on its end-to-end organ recovery platform.

"Acquisitions in this fragmented market aren't just about the attractive financial return, they can also expand our local service delivery area and enable us to provide additional services at lower cost to all of our customers," co-Chief Executive Melissa Tomkiel said.

In addition to revenue projections, Strata said it would have between $15 million and $22 million in free cash flow in 2026, before aircraft and engine acquisitions, and projected about $200 million of cash available through 2029.

Shares are down 9% to $4.36 in afternoon trading, but are up 40% in the last 52 weeks.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

November 17, 2025 15:07 ET (20:07 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.